As demand for our QTc studies grows, we recently introduced new Holter and Telemetry equipment to enhance this crucial new service.When evaluating new medicines during early phase clinical trials, it is crucial that the impact on the cardiovascular system is monitored continuously. Furthermore, the demand for QTc studies has increased due to undesired side-effects of medicines that prolong cardiac repolarization such as pimozide, thioridazine and cisapride.Ambulatory Holter monitoring as well as continuous Telemetry ECG monitoring are the two new services that we provide at Richmond complementing our QTc Study set up.Our Holter monitors allow the recording of ambulatory ECGs over a continuous period up to 48 hours, whilst not disturbing the normal daily routine of our volunteers. In addition, using our Telemetry system, volunteers are monitored 24 hours a day, 7 days a week whilst in the research unit.Having a dedicated team of Research Physicians who, in conjunction with Cardiologists from the St George's Hospital Medical School, constantly monitor the volunteers enables immediate access to volunteer information and helping to speed analysis and any necessary action.At Richmond Pharmacology we are dedicated to the well being and safety of volunteers. We continue to make every effort acquiring the latest technology to provide our clients with excellent clinical trial services.

Latest news

Richmond Pharmacology Announces Promotion of Dr Priscilla Ochuba to Associate Medical Director

August 1, 2025
Richmond Pharmacology is pleased to announce the promotion of Dr Priscilla Ochuba to Associate Medical Director, effective 1st August 2025.
Read more

Red4Research Blog – Alan’s Story

June 24, 2025
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Read more

Events

JSCPT 2025

5th –6th December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event